**Biomm S.A. (BIOM3) — Company Profile** Biomm S.A. is a Brazilian biotechnology company headquartered in Nova Lima, Minas Gerais, focused on the development, production, and commercialization of biopharmaceutical products, with a core emphasis on diabetes care and oncology. The company operates primarily in the Brazilian healthcare market, offering a portfolio that includes insulin products, biosimilars, and drug delivery devices. **Business Overview** Biomm’s flagship product is AFREZZA, an inhaled human insulin powder used for the treatment of diabetes. The company also markets GLARGILIN (glargine insulin), WOSULIN N and WOSULIN R, and …
Company Intelligence — Institutional Access
This dossier is part of our Company Intelligence database.
Full profiles, exchange dossiers and the regional intelligence briefs are available to institutional subscribers. Professional from US$490/year, Corporate US$1,450, Institutional US$3,900.
See institutional access →Already a subscriber? Log in.
Part of LatAm Company Intelligence
This company profile belongs to The Rio Times' research on every listed company and exchange in Latin America and the Caribbean. Browse the full intelligence hub →
Latest coverage
AgroGalaxy, Fertilizantes Heringer, and Biomm Post Losses in Q1 2024
Brazil’s Biomm Pharma signs agreement with Chinese CanSino to import Covid-19 vaccine
Brazil’s health regulator authorizes Biomm to conduct phase 3 trials of anti-Covid drug
Biomm closes deal to supply Covid-19 drug ‘Leronlimab’ to Brazil
Not ready to buy? Try Company Intelligence free for 14 days →
Editorial responsibility: Matthias Camenzind, Editor-in-Chief · Editorial standards · Report an error
Read More from The Rio Times
The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →